LIVN - LivaNova appoints new CFO; Q2 revenue exceeds expectations

LivaNova (LIVN) has appointed Alex Shvartsburg to the position of chief financial officer effective August 01.Shvartsburg, who served as the interim CFO since October 31, adds 25 years of relevant industry experience to the role, the company said, announcing its Q2 2021 results today.In the second quarter, the revenue from continuing operations has jumped 45.2% YoY to $264.5M on a reported basis, while revenue adjusted for the Heart Valves business, which was divested in June, stood at $249.8M, recording 51.6% YoY growth.Neuromodulation sales more than doubled to $117.6M indicating 102.4% YoY growth while cardiovascular sales gained 12.6% YoY to $145.9M.The second quarter diluted EPS for 2021 reached $0.52 on an adjusted basis. For Q2, the consensus revenue and EPS estimates stood at $244.1M and $0.33, respectively.The company expects its worldwide net sales from continuing operation to grow 5 – 10% on a constant-currency basis in 2021. The adjusted diluted EPS for

For further details see:

LivaNova appoints new CFO; Q2 revenue exceeds expectations